IMO, Gator, if TGD and Anavex enrolled DPZ-free (or weaned participants of it in a way-out period), then the percentages from the P2b/3 trial should be close to Mayo’s percentages.
As we know from the P2a trial, the 6 (7 through 31 weeks) who were DPZ-naive, demonstrated very strong positive results thru the first 31 and 57 weeks. Those on DPZ did not as they remained on the drug through that time period, as far as we know.
Keep the faith, Everyone.
P.S. Using a laptop, of which, I dislike.